Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab plus nab-paclitaxel and cisplatin induction therapy for newly treated locally advanced hypopharyngeal carcinoma
ChiCTR2200060094Phase 2Recruiting
- Sponsor
- Cancer Hospital, Chinese Academy of Medical Sciences
- Start
- May 2022
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab, paclitaxel and cisplatin in squamous cell carcinoma of the hypopharynx, sponsored by Cancer Hospital, Chinese Academy of Medical Sciences. Primary endpoints: objective response rate and 2-year overall survival rate. Started May 2022; status: recruiting.
02
Drugs
tislelizumabpaclitaxelcisplatin
03
Conditions
squamous cell carcinoma of the hypopharynx
Beyond the preview
Go deeper on ChiCTR2200060094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060094.